Published 5 hours ago • loading... • Updated 44 minutes ago
Merck Is Using Isomorphic Labs' AI to Design Cancer Drugs—but No Candidate Has Been Tested in Animals or People Yet
The pact gives Merck access to Isomorphic Labs’ AI drug design engine as the companies seek faster discovery of oncology candidates.
Summary by Medical Daily
4 Articles
4 Articles
Merck is using Isomorphic Labs' AI to design cancer drugs—but no candidate has been tested in animals or people yet
Merck and Google DeepMind spinout Isomorphic Labs will use AI to design small-molecule cancer drug candidates, but the research remains untested and far from human trials.
Merck and Isomorphic Labs Enter Strategic Research Collaboration
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience. The companies will collaborate to discover therapeutic small molecule candidates against a…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center2Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium








